Jean Cui

1.4k total citations
18 papers, 1.0k citations indexed

About

Jean Cui is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jean Cui has authored 18 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 11 papers in Molecular Biology and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jean Cui's work include Lung Cancer Treatments and Mutations (9 papers), Cancer therapeutics and mechanisms (5 papers) and Colorectal Cancer Treatments and Studies (4 papers). Jean Cui is often cited by papers focused on Lung Cancer Treatments and Mutations (9 papers), Cancer therapeutics and mechanisms (5 papers) and Colorectal Cancer Treatments and Studies (4 papers). Jean Cui collaborates with scholars based in United States, Italy and China. Jean Cui's co-authors include Sai‐Hong Ignatius Ou, A. John Iafrate, Mari Mino–Kenudson, Cynthia Huang Bartlett, Asaad Nematalla, Cho Tang, James Cheng‐Chung Wei, Yong Zhou, Hui Chen and Xueyan Wang and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Blood and Biochemistry.

In The Last Decade

Jean Cui

18 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jean Cui United States 10 518 427 407 231 141 18 1.0k
Haitian Quan China 17 492 0.9× 383 0.9× 662 1.6× 188 0.8× 137 1.0× 30 1.3k
Timothy J. Guzi United States 16 792 1.5× 258 0.6× 538 1.3× 261 1.1× 127 0.9× 31 1.4k
Jessica Orf United States 7 545 1.1× 437 1.0× 507 1.2× 97 0.4× 204 1.4× 9 1.3k
Akihiko Tsuruoka Japan 14 661 1.3× 388 0.9× 514 1.3× 286 1.2× 274 1.9× 30 1.7k
Chris Liang United States 13 581 1.1× 479 1.1× 463 1.1× 239 1.0× 125 0.9× 36 1.1k
Yongchang Shi United States 7 578 1.1× 447 1.0× 535 1.3× 86 0.4× 211 1.5× 9 1.3k
Sylvia Zhao China 12 488 0.9× 339 0.8× 419 1.0× 71 0.3× 119 0.8× 16 881
Brenda J Curry United Kingdom 7 814 1.6× 490 1.1× 768 1.9× 243 1.1× 247 1.8× 8 1.5k
Susan Ashton United Kingdom 14 580 1.1× 293 0.7× 521 1.3× 236 1.0× 161 1.1× 25 1.2k
Masao Iwata Japan 11 976 1.9× 209 0.5× 294 0.7× 147 0.6× 220 1.6× 13 1.6k

Countries citing papers authored by Jean Cui

Since Specialization
Citations

This map shows the geographic impact of Jean Cui's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jean Cui with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jean Cui more than expected).

Fields of papers citing papers by Jean Cui

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jean Cui. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jean Cui. The network helps show where Jean Cui may publish in the future.

Co-authorship network of co-authors of Jean Cui

This figure shows the co-authorship network connecting the top 25 collaborators of Jean Cui. A scholar is included among the top collaborators of Jean Cui based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jean Cui. Jean Cui is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Zhang, Lihong, Xia Yang, Zongjuan Ming, et al.. (2021). Molecular Characteristics of the Uncommon EGFR Exon 21 T854A Mutation and Response to Osimertinib in Patients With Non-Small Cell Lung Cancer. Clinical Lung Cancer. 23(4). 311–319. 8 indexed citations
2.
Zhu, Viola W., Misako Nagasaka, Russell W. Madison, et al.. (2020). A Novel Sequentially Evolved EML4-ALK Variant 3 G1202R/S1206Y Double Mutation In Cis Confers Resistance to Lorlatinib: A Brief Report and Literature Review. JTO Clinical and Research Reports. 2(1). 100116–100116. 27 indexed citations
3.
Bemark, Mats, et al.. (2019). Repotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma cells. Scientific Reports. 9(1). 19353–19353. 16 indexed citations
4.
Chaib, Imane, Xueting Cai, David Lligé, et al.. (2019). Osimertinib and dihydroartemisinin: a novel drug combination targeting head and neck squamous cell carcinoma. Annals of Translational Medicine. 7(22). 651–651. 14 indexed citations
5.
Chaib, Imane, Xueting Cai, David Lligé, et al.. (2019). Osimertinib and Dihydroartemisinin: A Novel Drug Combination Targeting Head and Neck Squamous Cell Carcinoma. SSRN Electronic Journal. 1 indexed citations
6.
Yoda, Satoshi, Leila Dardaei, Kylie Prutisto-Chang, et al.. (2018). Abstract 4795: Potency of a new ALK/ROS1 inhibitor TPX-0005 to ALK G1202R mutation and ROS1 G2032R mutation. Cancer Research. 78(13_Supplement). 4795–4795. 1 indexed citations
7.
8.
Deng, Wei, David C.S. Huang, Dayong Zhai, Evan Rogers, & Jean Cui. (2017). Abstract 3168: Overcoming acquired drug resistance by TPX-0005, an ALK, ROS1 and pan-TRK inhibitor. Cancer Research. 77(13_Supplement). 3168–3168. 1 indexed citations
9.
Ou, Sai‐Hong Ignatius, Cynthia Huang Bartlett, Mari Mino–Kenudson, Jean Cui, & A. John Iafrate. (2012). Crizotinib for the Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: A Success Story to Usher in the Second Decade of Molecular Targeted Therapy in Oncology. The Oncologist. 17(11). 1351–1375. 160 indexed citations
10.
Sach, Neal W., Michelle Tran‐Dubé, Huichun Zhu, et al.. (2012). Synthesis of Aryl Ethers via a Sulfonyl Transfer Reaction. Organic Letters. 14(15). 3886–3889. 28 indexed citations
11.
McTigue, Michele, Sergei Timofeevski, Wei Liu, et al.. (2011). Abstract 2327: Structural and kinetic characterization of crizotinib with wild-type and mutant anaplastic lymphoma kinase. Cancer Research. 71(8_Supplement). 2327–2327. 1 indexed citations
12.
Timofeevski, Sergei, Michele McTigue, Kevin Ryan, et al.. (2009). Enzymatic Characterization of c-Met Receptor Tyrosine Kinase Oncogenic Mutants and Kinetic Studies with Aminopyridine and Triazolopyrazine Inhibitors. Biochemistry. 48(23). 5339–5349. 75 indexed citations
13.
Guilhot, François, Alan K. Hatfield, Frédéric Millot, et al.. (2009). Accidental and Intentional Overdose of Imatinib: a Report of Outcome and Side Effect of 46 Cases.. Blood. 114(22). 4273–4273. 1 indexed citations
14.
Cui, Jean. (2006). Inhibitors targeting hepatocyte growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases. Expert Opinion on Therapeutic Patents. 16(5). 713–718. 7 indexed citations
15.
16.
Schiering, Nikolaus, Stefan Knapp, M. Marconi, et al.. (2003). Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a. Proceedings of the National Academy of Sciences. 100(22). 12654–12659. 118 indexed citations
17.
Sun, Li, Jean Cui, Congxin Liang, et al.. (2002). Rational design of 4,5-disubstituted-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-ones as a novel class of inhibitors of epidermal growth factor receptor (EGF-R) and Her2(p185erbB) tyrosine kinases. Bioorganic & Medicinal Chemistry Letters. 12(16). 2153–2157. 20 indexed citations
18.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Haitian Quan Breakdown of academic impact, for papers by Timothy J. Guzi Breakdown of academic impact, for papers by Jessica Orf Breakdown of academic impact, for papers by Akihiko Tsuruoka Breakdown of academic impact, for papers by Chris Liang Breakdown of academic impact, for papers by Yongchang Shi Breakdown of academic impact, for papers by Sylvia Zhao Breakdown of academic impact, for papers by Brenda J Curry Breakdown of academic impact, for papers by Susan Ashton Breakdown of academic impact, for papers by Masao Iwata
Rankless by CCL
2026